Company / Tangible Book Value per Share
Ultragenyx Pharmaceutical Inc. Tangible Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
-$1.34
FY2025
5-year range
-$1.34 / $9.12
FY2021-FY2025
Trend
-152.3%
vs FY2024
Sector context
#191 of 209
Health Care
What the data says
Among 209 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 9% for tangible book value per share. Tangible Book Value per Share has declined for 5 consecutive years, from $9.76 in FY2020 to $-1.34 in FY2025.
Based on SEC 10-K filings.
-1.34 in FY2025.
Declined from $3.28 to $-1.34 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 209This company -$1.34 Sector average $93.47
▼
-101.4% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s tangible book value per share has declined for 5 consecutive years.
- In FY2025, tangible book value per share decreased 152.3% year-over-year.
- Ranks #191 out of 209 companies in the Health Care sector.
- Peak tangible book value per share was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.34 | -152.3% |
| FY2024 | $2.56 | -22.0% |
| FY2023 | $3.28 | -25.9% |
| FY2022 | $4.44 | -51.4% |
| FY2021 | $9.12 | -6.6% |
| FY2020 | $9.76 | +46.4% |
| FY2019 | $6.67 | -47.8% |
| FY2018 | $12.78 | +8.3% |
| FY2017 | $11.80 | +148.1% |
| FY2016 | $4.76 | -67.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026